San Francisco – April 27, 2017 – Cooley advised the underwriters on Audentes Therapeutics’ $86.3 million shelf-takedown offering of 5,955,151 shares of common stock, which includes 755,151 shares purchased pursuant to the underwriters’ option to purchase additional shares.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager.
Audentes Therapeutics, which trades on The NASDAQ Global Market as "BOLD," is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.
In 2016, Cooley advised the underwriters on Audentes Therapeutics’ $85 million initial public offering.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.